Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W L Dunn

Showing results (81-90 of 81) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 81 results.
European Journal of Nuclear Medicine|August 22, 2000
Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphomaG A Wiseman, C A White, M Stabin, et al.
Pageof 9

Showing results (81-90 of 81) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 81 results.
European Journal of Nuclear Medicine|August 22, 2000
Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphomaG A Wiseman, C A White, M Stabin, et al.
Pageof 9